Pharma News

pharma courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Academically Revolutionizes GPAT/NIPER Preparation with India’s First Adaptive AI Technology-Based Curriculum
    4 December 2024

    Academically Revolutionizes GPAT/NIPER Preparation with India’s First Adaptive AI Technology-Based Curriculum

    Academically Global, India’s first Healthcare EdTech platform dedicated to preparing students for licensing exams and providing end-to-end support to facilitate international migration, has exclusively launched an Advanced Preparation Course for the Graduate Pharmacy Aptitude Test (GPAT) and National Institute of Pharmaceutical Education and Research Joint Entrance Exam (NIPER JEE).

  • 3 December 2024
    Bacteria modify ribosomes to dodge antibiotics
    Bacteria modify their ribosomes when exposed to widely used antibiotics, according to research published in Nature Communications. The subtle changes might be enough to alter the binding site of drug targets and constitute a possible new mechanism of antibiotic resistance.
  • 3 December 2024
    Some cancer treatments boost risk of heart disease, new mechanism found
    A cancer therapy that prompts the bodys immune defenses against viruses and bacteria to attack tumors can make patients more vulnerable to heart attack and stroke. A possible explanation for this side effect is that the treatment interferes with immune regulation in the largest blood vessels of heart
  • 2 December 2024
    Different menopausal hormone treatments pose different risks

    Researchers have analysed the effects of seven different hormone treatments for menopausal symptoms, and the risk of blood clots, stroke and heart attack. The risks differ depending on the active substance and how the medicine is taken. The study involves around one million women aged 50-58 and is the largest and most comprehensive study of currently prescribed hormonal substances in the world. 

  • 2 December 2024
    Monash study unravels another piece of the puzzle in how cancer cells may be targeted by the immune system

    Effective immunity hinges on the ability to sense infection and cellular transformation. In humans, there is a specialised molecule on the surface of cells termed MR1. MR1 allows sensing of certain small molecule metabolites derived from cellular and microbial sources; however, the breadth of metabolite sensing is unclear.

  • 29 November 2024
    New study reveals genetic drivers of early onset type 2 diabetes in South Asians 

    The findings, published today in Nature Medicine, show that these genetic factors also lead to quicker development of health complications, earlier need for insulin treatment, and a weaker response to some medications. The results of this research, funded by Barts Charity and Wellcome, reinforce the need to understand how genetic variation across different population groups can influence the onset of diseases, treatment responses, and disease progression. 

  • 29 November 2024
    Dr. Reddy's launches Toripalimab in India
    Toripalimab is a New Biological Entity. It is the only immuno-oncology drug approved by various regulatory authorities around the world such as the United States Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma.
  • 29 November 2024
    Study Details How Cancer Cells Fend Off Starvation & Death from Chemotherapy

    Laboratory experiments with cancer cells reveal two ways in which tumors evade drugs designed to starve and kill them, a new study shows.

  • 29 November 2024
    Abbott launches 14 valent Pneumococcal Conjugate Vaccine (PCV-14) That Offers Broadest Protection for Children Against Pneumococcal Bacterial Infections

    Abbott, the global healthcare leader, announced today the launch of its Pneumococcal Conjugate Vaccine, PneumoShield 14, for children over 6 weeks of age. Abbott’s PCV-14 valent (Pneumococcal Conjugate Vaccine), offers broad protection, covering the highest number of serotypes, or strains, as compared to existing PCV-10 and PCV-13 vaccines.

  • 28 November 2024
    Cervical cancer deaths in young women plummet after introduction of HPV vaccine

    Cervical cancer deaths have plunged dramatically among women under age 25, and researchers at MUSC Hollings Cancer Center believe this is likely due to HPV vaccination. Their study, published in JAMA, is the first to suggest the impact of HPV vaccination on cervical cancer deaths.

Subscribe to Pharma News